1 mg, 5 mg, 10 mg
Formula / molecular Weight
47kDa (GST fusion protein).
> 95% by SDS-PAGE analysis.
- By injecting sRANKL, novel osteopenia model mice were established in only 50 hours.
- Degree of bone loss can be controlled by changing doses of sRANKL
- High Activity and low endotoxin level.
- sRANKL can be used in establishing osteopenia model for in vivo screening of drugs for osteoporosis, determination of effect and mechanism, evaluation of bone anabolic drugs.
- Low Endotoxin Protein - 0.01 ng/mg (0.1 EU/µg).